Bevacizumab Improves Responses, PFS in Advanced Head and Neck Cancer

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

This video highlights results of a phase III randomized trial that tested chemotherapy plus bevacizumab in patients with recurrent or metastatic head and neck cancer.

In this video, Barbara Burtness, MD, of the Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, discusses results of E1305, a phase III randomized trial that tested chemotherapy with or without bevacizumab in patients with recurrent or metastatic squamous cell head and neck cancer.

Burtness presented results of the study (abstract 6000) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.

Related Videos
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD, spoke to the potential of ELI-002 2P as a treatment for minimal residual disease positivity in patients with KRAS-mutant solid tumors.
head and neck cancer
head and neck cancer
Related Content
FDA Gives Fast Track Designation to LYT-200 in Advanced Head and Neck Cancers

FDA Gives Fast Track Designation to LYT-200 in Advanced Head and Neck Cancers

April 12th 2024
Article

LYT-200 is currently being investigated for those with solid tumors and hematologic malignancies.

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Oncology On-The-Go Podcast: ASCO 2023 Recap

June 19th 2023
Podcast

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Radiation Therapy Plus Chemo Yielded Increased Efficacy in HPV+ Oropharynx Cancer

Radiation Therapy Plus Chemo Yielded Increased Efficacy in HPV+ Oropharynx Cancer

March 4th 2024
Article

The use of postoperative adjuvant radiation therapy led to less weight loss in patients with HPV-positive oropharynx cancer, according to Wade L. Thorstad, MD.

Using Germline Testing to Inform Treatment Decisions in Breast Cancer

Using Germline Testing to Inform Treatment Decisions in Breast Cancer

May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the use of germline testing and PARP inhibitors in patients with breast cancer with Jennifer K. Litton, MD.

The FDA grants clearance to an oral immobilization stent designed to redirect radiation to the target tumor area for patients with head and neck cancer.

FDA Clears Oral Stent Solution for Radiotherapy in Head and Neck Cancer

January 22nd 2024
Article

The FDA grants clearance to an oral immobilization stent designed to redirect radiation to the target tumor area for patients with head and neck cancer.

After observing a prevalence of thyroid cancer among transgender female patients through clinical observation, a study was prompted by clinicians in order to determine if this is an issue in a larger population.

Thyroid Cancer Rates Are Higher Among Transgender Female Veterans

October 29th 2023
Article

Study shows a high prevalence of thyroid cancer in transgender female patients.